Letters to the Editor

Outcomes of patients with primary central nervous system lymphoma following CD19-targeted chimeric antigen receptor T-cell therapy

Utah Transplant and Cellular Therapy Program, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT
Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI
Division of Biostatistics, Institute for Health and Equity, Medical College of Wisconsin, Milwaukee, WI
Department of Medicine, Weill Cornell Medicine, Cornell University, New York, NY; Section of Hematology, Houston Methodist Hospital and Neal Cancer Center, Houston, TX
Harold C. Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas, TX
Division of Hematologic Malignancies and Cellular Therapy, Department of Medicine, Duke University School of Medicine, Durham, NC
Division of Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY
Division of Hematology-Oncology and Blood and Marrow Transplantation and Cellular Therapy Programs, Mayo Clinic, Jacksonville, FL
Division of Hematology/Oncology, Department of Internal Medicine, Blood and Marrow Transplantation Program, University of Michigan Medical School, Ann Arbor, MI
Department of Hematology-Oncology, Montefiore Medical Center/Albert Einstein College of Medicine, Bronx, NY
Blood and Marrow Transplant Program, Northside Hospital, Atlanta, GA
Rush University Medical Center, Chicago, IL
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Hematology/Medical Oncology, Cleveland Clinic, Cleveland, OH
BMT and Cellular Therapy Program, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI; Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI
City of Hope, Duarte, CA
Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA
Haematologica Early view Sep 5, 2024 https://doi.org/10.3324/haematol.2024.285613